Phase III trial of osilodrostat in Cushing’s Disease meets primary endpoint

In the LINC-4 study, which included patients with Cushing’s for whom pituitary surgery was not appropriate or was not curative, more patients receiving osilodrostat than placebo achieved normal mean urinary free cortisol after 12 weeks of treatment (77% vs 8%; p<0.0001).

SPS commentary:

Osilodrostat was approved in the EU in January 2020. It is licensed in the UK but there are as yet no plans for its launch.


Biospace Inc.